Long-term use of foscarnet is associated with an increased incidence of acute kidney injury in hematopoietic stem cell transplant patients: A retrospective observational study.

Ryo Inose Katsuyuki TakahashiMasaya TakahashiTakashi SugimotoSatoru NannoMasayuki HinoKatsuya Nagayama

Published in: Transplant infectious disease : an official journal of the Transplantation Society (2022)

The incidence of AKI was 51.1% in HSCT patients treated with foscarnet, and foscarnet administration for more than 27 days may be associated with the incidence of AKI.

Keyphrases

hematopoietic stem cell
risk factors
acute kidney injury
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
patient reported